Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HK1 | P19367 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276388 | 0.96 | PTGDR2 (0.41) | PTGDR2TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL3275720 | 0.95 | MCL1 (0.44) | PTGDR2TP53KMT2AMEN1ALDH1A1 | |
| SCHEMBL3277262 | 0.93 | KMT2A (0.44) | PTGDR2KMT2AMEN1ALDH1A1HK1 | |
| SCHEMBL3277176 | 0.91 | PTGDR2 (0.41) | PTGDR2TP53KMT2AMEN1PTGIR | |
| SCHEMBL3275173 | 0.89 | KMT2A (0.46) | PTGDR2KMT2AMEN1ALDH1A1HK1 | |
| SCHEMBL3277567 | 0.88 | KMT2A (0.43) | PTGDR2KMT2AMEN1ALDH1A1HK1 | |
| SCHEMBL3281152 | 0.88 | KMT2A (0.49) | PTGDR2KMT2AMEN1ALDH1A1HK1 | |
| SCHEMBL3277431 | 0.86 | POLB (0.43) | PTGDR2TP53KMT2AMEN1MCL1 | |
| SCHEMBL3282727 | 0.86 | POLB (0.46) | TP53KMT2AMEN1MCL1POLB | |
| SCHEMBL3279636 | 0.84 | KMT2A (0.43) | PTGDR2TP53KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | claimed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | claimed |
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696240-B2 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1966134-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068621-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142452-A1 | Fused pyrrole derivatives | CMA1, PREP, CPA3 | PTGDR2 414/4885TP53 1734/4885KMT2A 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.